GRAL Grail
- 16.920
- -2.900-14.63%
- 17.000
- +0.080+0.47%
Grail News
Express News | GRAIL Shares Are Trading Lower. The Company Announced That the First Participant Has Been Enrolled in the REACH/Galleri-Medicare Study at Community Health Network
Express News | Grail Inc - Medicare to Cover Costs for Galleri Study Participants
Express News | Grail Announces First Participant Enrolled in Reach Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (Mced) Test in the Medicare Population
Dow, S&P 500 Hit Closing Records as Markets Weigh Retail Sales Report, Earnings
The Dow Jones Industrial Average and the S&P 500 closed at all-time highs Tuesday as markets assessed official retail sales data for June and the latest corporate earnings.The Dow jumped 1.9% to 40,95
GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
Express News | GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Health care stocks were edging higher premarket Monday with the Health Care Select Sector SPDR Fund (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) recently advancing by 0.4%.ASLAN
The New Holy Grail for Weight-Loss Drugs Is Sleep Apnea -- WSJ
Whether millions of people will be able to afford one of the hot new weight-loss drugs could hinge on whether they cure the sleep apnea of people like Damon Sedgwick.
Grail Completes Enrollment in US Study for Cancer Early-Detection Device
Grail Inc. (GRAL) said Monday it has completed the enrollment of more than 35,000 people for its US study of Galleri, the company's potential multi-cancer early detection test, at more than 30
Express News | Grail Inc - Final Results From Nhs-Galleri Trial Expected in 2026
Express News | Grail Advances the Galleri® Registrational Clinical Trial Program
Illumina Takes a $1.47 Billion Charge Related to Its GRAIL Spinoff
Gene-sequencing Group Illumina Sees $1.47 Bn Q2 Impairment Charge Linked to Grail
Express News | Grail Inc - Estimates That It Will Recognize a Goodwill Impairment Charge in Q2 of 2024 Equal to $888.9 Mln
Express News | Illumina Inc - Estimates That It Will Recognize an Impairment Charge for Grail Ipr&D Intangible Asset in Q2 of 2024 Equal to $420 Mln
Express News | Summit Therapeutics Appoints Jeff Huber, Transformational Google and Grail Executive, to Its Board of Directors
With a valuation of $8 billion, can the dream of Grail (GRAL.US) last after the failure of the Yanmen Pass?
After three years of struggle and tug-of-war, Illumina finally announced the divestiture of Grail on December 17th of last year. And this former unicorn also began its delayed U.S. stock market IPO four years later and officially listed on Nasdaq on June 25th this year, followed by a drama of "nearly 20% drop on the first day" for investors.
News On GRAIL Inc. (GRALV) Now Under GRAL
News On GRAIL Inc. (GRALV) Now Under GRAL
Express News | Cancer Test Maker Grail's Shares Fall 12.3% to $16.34 Each on Nasdaq Debut After Opening at $18.35 per Share
Express News | GRAIL Shares Resume Trading
Analysis
Price Target
No Data
